中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

160 records (took 0.026 seconds)

    NEW CATH2 DERIVATIVES
    1.
    发明申请
    NEW CATH2 DERIVATIVES 审中-公开
    新CATH2衍生物

    公开(公告)号：WO2015170984A1

    公开(公告)日：2015-11-12

    申请号：PCT/NL2015/050323

    申请日：2015-05-08

    Applicant: UNIVERSITEIT UTRECHT HOLDING B.V.

    Inventor： HAAGSMAN, Hendrik Peter ,  VAN DIJK, Albert ,  VELDHUIZEN, Edwin Johannes Adrianus

    IPC: C07K4/12 ,  C07K7/08 ,  C07K14/465 ,  A61K38/17

    CPC classification number: C07K14/465 ,  A61K38/00

    Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retro-inverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.

    Abstract translation: 本发明提供CATH2或CMAP27的新衍生物，其为导管素之一。 这些衍生物包括N-末端截短的肽，环肽，CATH2的D-氨基酸变体及其截短的衍生物，反转和反转式CATH2衍生物。 这些衍生物作为抗感染剂，疫苗，尤其是在ovo应用中是有用的。 此外，对于上述衍生物以及已知的C末端截短衍生物，已经描述了对预防性治疗特别有利的新的免疫活化功能。

    LIPID CO-FACTOR ESSENTIAL FOR CELL DENSITY SIGNALING
    2.
    发明申请
    LIPID CO-FACTOR ESSENTIAL FOR CELL DENSITY SIGNALING 审中-公开
    脂质因子对细胞密度信号的依赖性

    公开(公告)号：WO2015066080A3

    公开(公告)日：2015-06-25

    申请号：PCT/US2014062729

    申请日：2014-10-28

    Applicant: UNIV CALIFORNIA ,  SCHWARZ RICHARD I

    Inventor： SCHWARZ RICHARD I

    IPC: B01D15/00

    CPC classification number: C07F9/5722 ,  B01D61/145 ,  B01D61/16 ,  C07K14/465 ,  C07K14/47 ,  C07K14/4705 ,  C07K16/18

    Abstract: Herein we describe, a candidate gene for the diffusible cell density signal is put through the classic test to validate its activity: ectopic expression in another cell type from another species, purification of the recombinant factor, and testing back on PAT cells to see if it acts like the original diffusible cell density signal. This classic approach is complicated by the finding that the cell type producing this protein binds a unique tissue-specific lipid cofactor and this composite molecule imparts a tissue-specific response. Previously, this mechanism was shown to rely on a diffusible factor with an affinity for the cell layer.

    Abstract translation: 在本文中，我们描述了扩散细胞密度信号的候选基因通过经典测试来验证其活性：来自另一物种的另一种细胞类型的异位表达，重组因子的纯化，以及在PAT细胞上测试 像原始扩散细胞密度信号一样。 这种经典方法通过发现产生该蛋白的细胞类型结合独特的组织特异性脂质辅因子的发现而变得复杂，并且该复合分子赋予组织特异性应答。 以前，这种机制显示依赖于对细胞层具有亲和性的扩散因子。

    CELL PERMEABLE MINIATURE PROTEINS
    5.
    发明申请
    CELL PERMEABLE MINIATURE PROTEINS 审中-公开
    细胞渗透微量蛋白

    公开(公告)号：WO2008133929A2

    公开(公告)日：2008-11-06

    申请号：PCT/US2008005264

    申请日：2008-04-24

    Applicant: UNIV YALE ,  SCHEPARTZ ALANNA S ,  DANIELS DOUGLAS S ,  SMITH BETSY

    Inventor： SCHEPARTZ ALANNA S ,  DANIELS DOUGLAS S ,  SMITH BETSY

    IPC: C07K14/465 ,  C07K14/47

    CPC classification number: C07K14/465 ,  C07K14/47 ,  C07K14/575

    Abstract: The present invention generally relates to miniature proteins, including miniature proteins that are permeable to cells. Certain aspects of the invention are generally related to miniature proteins, such as avian pancreatic polypeptide (aPP), modified such that the miniature proteins are permeable to cells. For instance, a portion of the aPP, such as the alpha helix region and/or the type II polyproline helix region, may be modified to render the region substantially cationic. As an example, one or more residues may be substituted with cationic amino acid residues such as arginine. The miniature proteins may also have additional functions, such as the ability to bind to other proteins such as Bcl2 or hDM2. Another aspect of the invention is generally directed to sequences, such as PRR or PPR, that can be added to other proteins in order to increase their cell permeability. Still other aspects of the invention are generally directed to methods of making such proteins, methods of using such proteins, kits involving such proteins, and the like.

    Abstract translation: 本发明一般涉及微型蛋白质，包括细胞可渗透的微型蛋白质。 本发明的某些方面通常涉及微型蛋白质，例如禽胰腺多肽（aPP），其被修饰以使得微型蛋白质可渗透细胞。 例如，aPP的一部分，例如α螺旋区域和/或II型聚脯氨酸螺旋区域可以被修饰以使该区域基本上是阳离子的。 作为实例，一个或多个残基可以被阳离子氨基酸残基例如精氨酸取代。 微型蛋白质还可以具有附加功能，例如结合其他蛋白质如Bcl2或hDM2的能力。 本发明的另一方面通常涉及可以加入其它蛋白质以增加其细胞渗透性的序列，例如PRR或PPR。 本发明的其它方面通常涉及制备这种蛋白质的方法，使用这些蛋白质的方法，涉及这种蛋白质的试剂盒等。

    COMPOSITIONS INCLUDING DIFFERENT TYPES OF TRANSFER FACTOR, METHODS FOR MAKING THE COMPOSITIONS, AND METHODS OF TREATMENT USING THE COMPOSITIONS
    7.
    发明申请
    COMPOSITIONS INCLUDING DIFFERENT TYPES OF TRANSFER FACTOR, METHODS FOR MAKING THE COMPOSITIONS, AND METHODS OF TREATMENT USING THE COMPOSITIONS 审中-公开
    包括不同类型的转运因子的组合物，用于制备组合物的方法和使用组合物的治疗方法

    公开(公告)号：WO2005028622A2

    公开(公告)日：2005-03-31

    申请号：PCT/US2004/030307

    申请日：2004-09-15

    Applicant: 4LIFE RESEARCH, LC ,  LISONBEE, David ,  HENNEN, William, J. ,  DAUGHERTY, F., Joseph

    Inventor： LISONBEE, David ,  HENNEN, William, J. ,  DAUGHERTY, F., Joseph

    IPC: C12N

    CPC classification number: C07K14/52 ,  A61J3/074 ,  A61K35/00 ,  C07K14/465

    Abstract: A composition for eliciting a T-cell mediated immune response in a subject includes transfer factor from at least two different types of source animals. For example, the composition may include mammalian transfer factor and nonmammalian transfer factor. An example of the composition includes a combination of a colostrum-derived product, which includes the mammalian transfer factor, and an egg-derived product, which includes the nonmammalian transfer factor. Additionally, the egg-derived product may be substantially free of fat. Methods for forming the composition and eliciting T-cell mediated immune responses in subjects that have been treated with the composition are also disclosed.

    Abstract translation: 在受试者中引发T细胞介导的免疫应答的组合物包括来自至少两种不同类型的源动物的转移因子。 例如，组合物可以包括哺乳动物转移因子和非哺乳动物转移因子。 组合物的实例包括包含哺乳动物转移因子的初乳衍生产物和包含非哺乳动物转移因子的卵衍生产物的组合。 另外，卵衍生的产品可以基本上不含脂肪。 还公开了在已经用组合物处理的受试者中形成组合物并引发T细胞介导的免疫应答的方法。

    RECOMBINANT VITELLOGENIN ENRICHED FEED
    9.
    发明申请
    RECOMBINANT VITELLOGENIN ENRICHED FEED 审中-公开
    重组维生素E加入饲料

    公开(公告)号：WO2004044185A1

    公开(公告)日：2004-05-27

    申请号：PCT/SG2003/000266

    申请日：2003-11-12

    Applicant: NATIONAL UNIVERSITY OF SINGAPORE ,  DING, Jeak, Ling ,  LIM, Eng, Hwa ,  LAM, Toong, Jin

    Inventor： DING, Jeak, Ling ,  LIM, Eng, Hwa ,  LAM, Toong, Jin

    IPC: C12N1/19

    CPC classification number: C12N15/81 ,  A23K10/18 ,  A23K20/147 ,  A23K20/158 ,  A23K50/80 ,  C07K14/465

    Abstract: The invention provides an expression vector for expression of recombinant vitellogenin in an eukaryotic host. An eukaryotic host, including yeast comprising the expression vector according to the invention may be used as a feed or feed additive for both oviparous and non-oviparous animals, including domesticated animals. A transgenic yeast according to the invention contain increased levels of essential amino acids and fatty acids and may be used as a direct feed or fed to an intermediate live feed such as rotifers or artemias to increase the survival rates of oviparous animal or broodstock.

    Abstract translation: 本发明提供了用于在真核宿主中表达重组卵黄发生素的表达载体。 包括本发明表达载体的酵母的真核宿主可以用作产卵和非生殖性动物（包括驯养动物）的饲料或饲料添加剂。 根据本发明的转基因酵母含有增加的必需氨基酸和脂肪酸的水平，并且可以用作直接饲料或饲喂到中间活饲料如轮虫或蒿中以增加产卵动物或亲体的存活率。

Patent Agency Ranking